Peroxiredoxin 1 inhibits tumorigenesis by activating the NLR family pyrin domain containing 3/gasdermin D pathway: Advanced therapies targeting heterogeneous cell death mechanisms

We read with great interest the advanced research article by He <i>et al</i>, which reported a marked upregulation of peroxiredoxin 1 mRNA and protein levels in colorectal cancer tissues. A central finding of this study was the demonstration of distinct heterogeneity in cell death mechanisms between normal and malignant cells. Current evidence indicates the existence of at least 12 subtypes of programmed cell death, each characterized by unique molecular signatures. The findings of this study have the potential to advance the development of personalized therapies that target cancer cells, representing a promising step forward in cancer treatment. Further advances in targeted mRNA therapy could be achieved by selectively shifting the regulation of cancer cells toward specific pathways of cellular death.